0000939767-23-000103.txt : 20230908
0000939767-23-000103.hdr.sgml : 20230908
20230908212253
ACCESSION NUMBER: 0000939767-23-000103
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230906
FILED AS OF DATE: 20230908
DATE AS OF CHANGE: 20230908
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hessekiel Jeffrey
CENTRAL INDEX KEY: 0001599803
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 231246503
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wk-form4_1694222563.xml
FORM 4
X0508
4
2023-09-06
0
0000939767
EXELIXIS, INC.
EXEL
0001599803
Hessekiel Jeffrey
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
0
1
0
0
EVP, General Counsel & Sec
0
Common Stock
2023-09-06
4
A
0
57900
0
A
622699
D
Common Stock
2023-09-06
4
F
0
14354
22.27
D
608345
D
Common Stock
999
I
By 401(k)
On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.
On September 6, 2023, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 150% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). The Reporting Person had already vested 1/3 of the Achieved Shares as a result of the Committee's certification that certain performance criteria had been achieved on August 3, 2022 and continuous service through August 15, 2023. Accordingly, the Committee's certification on September 6, 2023 resulted in the immediate vesting of 1/3 of the Achieved Shares, and 1/3 of the Achieved Shares will vest on November 15, 2024, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending on the level and timing of achievement of the performance criteria through December 31, 2024.
Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 6, 2023.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of September 5, 2023.
/s/ Nina Ayer, Attorney in Fact
2023-09-08